Privia Health Group Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
PRVA$24.37-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| For the Years Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities | |||
| Net income (loss) | $21,028 | $(12,064) | $(190,649) |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||
| Depreciation | 1,174 | 1,220 | 1,152 |
| Amortization of intangibles | 5,359 | 3,351 | 1,312 |
| Amortization of debt issuance costs | — | 687 | 157 |
| Stock-based compensation | 37,098 | 67,359 | 253,531 |
| Debt Issuance costs Amortization | — | — | — |
| Deferred tax expense (benefit) | 7,465 | (7,004) | (28,411) |
| Changes in asset and liabilities: | |||
| Accounts receivable | (96,877) | (72,202) | (14,642) |
| Prepaid expenses and other current assets | (6,159) | (5,669) | (1,269) |
| Other non-current assets and right-of-use asset | (2,418) | 1,383 | (9,680) |
| Accounts payable and accrued expenses | 4,994 | 6,852 | 1,262 |
| Provider liability | 113,367 | 67,716 | 33,897 |
| Operating lease liabilities | (3,214) | (2,433) | 13,936 |
| Other long-term liabilities | (1,032) | (2,000) | (5,538) |
| Net cash provided by operating activities | 80,785 | 47,196 | 55,058 |
| Cash flows from investing activities | |||
| Purchases of property and equipment | (113) | (104) | (547) |
| Business acquisitions, net of cash acquired | (42,858) | — | (32,228) |
| Net cash used in investing activities | (42,971) | (104) | (32,775) |
| Cash flows from financing activities | |||
| Proceeds from initial public offering | — | — | 223,685 |
| Payments of underwriting fees, net of discounts and offering costs | — | — | (12,691) |
| Repurchase of non-controlling interest | (5,694) | — | — |
| Proceeds from non-controlling interest | 659 | 125 | — |
| Repayment of note payable | — | (33,250) | (875) |
| Proceeds from exercised stock options | 8,740 | 13,448 | 3,829 |
| Debt issuance costs | — | — | (287) |
| Net cash provided by (used in) financing activities | 3,705 | (19,677) | 213,661 |
| Net increase in cash and cash equivalents | 41,519 | 27,415 | 235,944 |
| Cash and cash equivalents at beginning of period | 347,992 | 320,577 | 84,633 |
| Cash and cash equivalents at end of period | $389,511 | $347,992 | $320,577 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid | $40 | $713 | $888 |
| Income taxes paid | $1,040 | $307 | $504 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.